Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA [email protected].

Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.

Published in British Journal of Ophthalmology

The efficacy of mineralocorticoid receptor antagonist eplerenone to treat chronic central serous chorioretinopathy (CSCR) has been established. However, previous studies have been limited by small cohort size and short follow-up duration. This study aims to report 3-year clinical outcomes of patients treated with eplerenone for chronic CSCR. Instit...